Cargando…

An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars

Nanoparticles including nanomedicines are known to be recognised by and interact with the immune system. As these interactions may result in adverse effects, for safety evaluation, the presence of such interactions needs to be investigated. Nanomedicines in particular should not unintendedly interac...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandebriel, Rob J., David, Christopher A. W., Vermeulen, Jolanda P., Liptrott, Neill J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360168/
https://www.ncbi.nlm.nih.gov/pubmed/35838879
http://dx.doi.org/10.1007/s13346-022-01206-6
_version_ 1784764293459214336
author Vandebriel, Rob J.
David, Christopher A. W.
Vermeulen, Jolanda P.
Liptrott, Neill J.
author_facet Vandebriel, Rob J.
David, Christopher A. W.
Vermeulen, Jolanda P.
Liptrott, Neill J.
author_sort Vandebriel, Rob J.
collection PubMed
description Nanoparticles including nanomedicines are known to be recognised by and interact with the immune system. As these interactions may result in adverse effects, for safety evaluation, the presence of such interactions needs to be investigated. Nanomedicines in particular should not unintendedly interact with the immune system, since patient’s exposure is not minimised as in the case of ‘environmental’ nanoparticles, and repeated exposure may be required. NLRP3 inflammasome activation and dendritic cell (DC) maturation are two types of immune mechanisms known to be affected by nanoparticles including nanomedicines. NLRP3 inflammasome activation results in production of the pro-inflammatory cytokines IL-1β and IL-18, as well as a specific type of cell death, pyroptosis. Moreover, chronic NLRP3 inflammasome activation has been related to several chronic diseases. Upon maturation, DC activate primary T cells; interference with this process may result in inappropriate activation and skewing of the adaptive immune response. Here, we evaluated the effect of two nanomedicines, representing nanostructured lipid carriers and polymers, on these two assays. Moreover, with a view to possible future standardisation and regulatory application, these assays were subject to an inter-laboratory comparison study using common SOPs. One laboratory performed three independent NLRP3 inflammasome activation experiments, while the other performed a single experiment. Two laboratories each performed three independent DC maturation experiments. While the nanostructured lipid carrier only showed marginal effects, the polymers showed major cytotoxicity. No evidence for inflammasome activation or DC maturation was demonstrated. Intra- and inter-laboratory comparison showed clearly reproducible results. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13346-022-01206-6.
format Online
Article
Text
id pubmed-9360168
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-93601682022-08-10 An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars Vandebriel, Rob J. David, Christopher A. W. Vermeulen, Jolanda P. Liptrott, Neill J. Drug Deliv Transl Res Original Article Nanoparticles including nanomedicines are known to be recognised by and interact with the immune system. As these interactions may result in adverse effects, for safety evaluation, the presence of such interactions needs to be investigated. Nanomedicines in particular should not unintendedly interact with the immune system, since patient’s exposure is not minimised as in the case of ‘environmental’ nanoparticles, and repeated exposure may be required. NLRP3 inflammasome activation and dendritic cell (DC) maturation are two types of immune mechanisms known to be affected by nanoparticles including nanomedicines. NLRP3 inflammasome activation results in production of the pro-inflammatory cytokines IL-1β and IL-18, as well as a specific type of cell death, pyroptosis. Moreover, chronic NLRP3 inflammasome activation has been related to several chronic diseases. Upon maturation, DC activate primary T cells; interference with this process may result in inappropriate activation and skewing of the adaptive immune response. Here, we evaluated the effect of two nanomedicines, representing nanostructured lipid carriers and polymers, on these two assays. Moreover, with a view to possible future standardisation and regulatory application, these assays were subject to an inter-laboratory comparison study using common SOPs. One laboratory performed three independent NLRP3 inflammasome activation experiments, while the other performed a single experiment. Two laboratories each performed three independent DC maturation experiments. While the nanostructured lipid carrier only showed marginal effects, the polymers showed major cytotoxicity. No evidence for inflammasome activation or DC maturation was demonstrated. Intra- and inter-laboratory comparison showed clearly reproducible results. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13346-022-01206-6. Springer US 2022-07-15 2022 /pmc/articles/PMC9360168/ /pubmed/35838879 http://dx.doi.org/10.1007/s13346-022-01206-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Vandebriel, Rob J.
David, Christopher A. W.
Vermeulen, Jolanda P.
Liptrott, Neill J.
An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars
title An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars
title_full An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars
title_fullStr An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars
title_full_unstemmed An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars
title_short An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars
title_sort inter-laboratory comparison of an nlrp3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360168/
https://www.ncbi.nlm.nih.gov/pubmed/35838879
http://dx.doi.org/10.1007/s13346-022-01206-6
work_keys_str_mv AT vandebrielrobj aninterlaboratorycomparisonofannlrp3inflammasomeactivationassayanddendriticcellmaturationassayusingananostructuredlipidcarrierandapolymericnanomedicineasexemplars
AT davidchristopheraw aninterlaboratorycomparisonofannlrp3inflammasomeactivationassayanddendriticcellmaturationassayusingananostructuredlipidcarrierandapolymericnanomedicineasexemplars
AT vermeulenjolandap aninterlaboratorycomparisonofannlrp3inflammasomeactivationassayanddendriticcellmaturationassayusingananostructuredlipidcarrierandapolymericnanomedicineasexemplars
AT liptrottneillj aninterlaboratorycomparisonofannlrp3inflammasomeactivationassayanddendriticcellmaturationassayusingananostructuredlipidcarrierandapolymericnanomedicineasexemplars
AT vandebrielrobj interlaboratorycomparisonofannlrp3inflammasomeactivationassayanddendriticcellmaturationassayusingananostructuredlipidcarrierandapolymericnanomedicineasexemplars
AT davidchristopheraw interlaboratorycomparisonofannlrp3inflammasomeactivationassayanddendriticcellmaturationassayusingananostructuredlipidcarrierandapolymericnanomedicineasexemplars
AT vermeulenjolandap interlaboratorycomparisonofannlrp3inflammasomeactivationassayanddendriticcellmaturationassayusingananostructuredlipidcarrierandapolymericnanomedicineasexemplars
AT liptrottneillj interlaboratorycomparisonofannlrp3inflammasomeactivationassayanddendriticcellmaturationassayusingananostructuredlipidcarrierandapolymericnanomedicineasexemplars